Ganesh Murthy, MD
Epilepsy · Phoenix, AZNPI 1851702187
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,549 of the $8,091 with a category attached, or 80.9%. 34 manufacturers reported payments, led by Livanova USA, Inc. at 31.4% of the total. Reporting peaked in 2021 at $2,520 and has fallen 67.8% since, to $812 in 2025.
Across 198 payments — averaging $40.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$3K
- SK Life Science, Inc.$1K
- AbbVie$882
- UCB, Inc.$614
- Neuropace, Inc.$522
- Jazz Pharmaceuticals Inc.$485
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$6508%
- Travel & lodging$81710%
- Food & beverage$6,54981%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 29 | $2,541 |
| SK Life Science, Inc. | 14 | $1,018 |
| AbbVie | 42 | $882 |
| UCB, Inc. | 15 | $614 |
| Neuropace, Inc. | 17 | $522 |
| Jazz Pharmaceuticals Inc. | 6 | $485 |
| Sunovion Pharmaceuticals Inc. | 9 | $221 |
| Neurelis, Inc. | 5 | $220 |
| Medtronic | 2 | $206 |
| Roche Diagnostics Corporation | 1 | $123 |
| Catalyst Pharmaceuticals, Inc. | 2 | $120 |
| AstraZeneca | 7 | $116 |
| Monteris Medical Corporation | 1 | $103 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $98 |
| Eisai Inc. | 3 | $85 |
| Teva Pharmaceuticals USA, Inc. | 5 | $83 |
| Pacira Pharmaceuticals Incorporated | 2 | $71 |
| Amgen | 4 | $65 |
| Pfizer | 3 | $64 |
| Lundbeck LLC | 3 | $59 |
| Lilly USA, LLC | 4 | $58 |
| Biogen | 3 | $56 |
| Sumitomo Pharma America, Inc. | 4 | $48 |
| Johnson & Johnson | 2 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| CSL Behring | 1 | $25 |
| Argenx US, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Zogenix Inc. | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS - Sentiva$1,401
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$400
- Epidiolex$300
- Briviact$251
- Fintepla$122
- XCOPRI$117
- RNS Neurostimulator Kit$114
- VALTOCO$107
- PERCEPT PC BRAINSENSE$105
- Neuroblate$103
- SenSight$100
How this compares
Too few epilepsy providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 184 | $260,070 |
| AptiomEslicarbazepine Acetate | 104 | $228,007 |
| EpidiolexCannabidiol (Cbd) | 40 | $202,387 |
| BriviactBrivaracetam | 106 | $153,794 |
| FycompaPerampanel | 61 | $79,175 |
| Nurtec OdtRimegepant Sulfate | 22 | $40,328 |
| Clobazam | 156 | $35,816 |
| UbrelvyUbrogepant | 28 | $33,103 |
| NayzilamMidazolam | 26 | $26,136 |
| Aimovig AutoinjectorErenumab-Aooe | 34 | $24,557 |
| Lacosamide | 203 | $20,510 |
| Trokendi XrTopiramate | 12 | $12,316 |
| Levetiracetam | 262 | $12,169 |
| Lamotrigine ErLamotrigine | 24 | $10,382 |
| Lamotrigine | 207 | $6,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $1,018 | $260,070184 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $221 | $228,007104 claims |
| UCB, Inc.Briviact, Nayzilam | $614 | $179,929132 claims |
| Eisai Inc.Fycompa | $85 | $79,17561 claims |
| PfizerNurtec Odt, Dilantin | $64 | $42,04534 claims |
| AbbVieUbrelvy | $882 | $33,10328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other epilepsy in Phoenix
- Daniel FayardPhoenix$8K
- Matthew HoerthPhoenix$3K
- Susan HermanPhoenix$3K
- David HarrisPhoenix$2K
- Courtney SchussePhoenix$1K
- Vladimir ShvartsPhoenix$1K
- Michael SteinPhoenix$635
- Kevin ChoiPhoenix$422
- Laura LehnhoffPhoenix$272
- Deana GazzolaPhoenix$236
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.